In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Neuroprotective Agents (2)

Edited by Edited by William Slikker, Jr. (National Center for Toxicological Research/FDA, Jefferson, Arkansas) and Bruce Trembly (VA Medical Center, Togus, Maine)
Neuroprotective Agents (2)

Published: June 2001

Volume 939

Learn More

An international group of scientists in both clinical and basic research examine the effects of and therapy for spinal cord injury; inflammatory responses in intracerebral hemorrhage; neurotoxicity and genetic damage from amphetamine abuse; effects of marijuana abuse; cerebrovascular deficits; effects of and therapy for ischemic stroke; distribution of microglia in aging brain and after transgenic manipulation; preconditioning gene induction for neuroprotection against oxidative stress; interaction of genes and environment in the expression and treatment of autism in an animal model; pathology and pharmacology of spreading depression. The volume also examines proposed designs and strategies for neuroprotection trials.

This volume is out of print.